ADHD Statistics Updated November 2026

Human Written & Fact Checked · Updated

100 ADHD in Children Statistics for 2026

Before you compare childhood ADHD numbers, check what was counted. A parent reporting a diagnosis, a clinical assessment and a pharmacy dispensing record answer different questions. This hub keeps those boundaries visible so you can quote the evidence without turning service activity into disease prevalence.

The US and Canadian sections describe parent-reported professional diagnoses. The Australian sections follow adolescent medication dispensing. Together, they show the scale and distribution of recognized ADHD and the services surrounding it, while preserving each study's age range and reference period. They do not establish a worldwide prevalence estimate or identify which treatment an individual child needs.

Headline figures

  • US all children aged 3–17: parent-reported current ADHD diagnosis, 11.7% in 2024. (HRSA, Jul 2026)
  • US boys aged 12–17: parent-reported current ADHD diagnosis, 17.5% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: unmet health-care need in the previous year, 8.3% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: less-than-very-satisfied parental care-coordination ratings in the previous year, 43.4% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: current ADHD medication, 53.6% in 2022. (Danielson et al. / CDC and HRSA, May 2024)
  • US children with current ADHD: ADHD behavioral treatment during the previous year, 44.4% in 2022. (Danielson et al. / CDC and HRSA, May 2024)
  • US children with current ADHD: a telehealth visit in the previous year, 31.6% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: a hospital admission in the previous year, 4.7% in 2024. (HRSA, Jul 2026)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among all children aged 1 to 17, 9.6%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among females aged 12 to 17, 11.2%. (Statistics Canada, Nov 2025)
  • Australia, 2023–24: ADHD-medication patients among all adolescents aged 12–17, 69 per 1,000 population. (Australian Department of Health / AIHW, May 2026)
  • Australia, 2023–24: ADHD-medication patients among females aged 12–17, 50 per 1,000 population. (Australian Department of Health / AIHW, May 2026)

How common is current ADHD among US children?

Age-specific diagnosis estimates are more informative than a single headline. These figures describe recognition by a health professional as reported by a parent, followed by confirmation that the condition was current.

How does reported diagnosis vary across childhood?

  • US boys aged 3–17: parent-reported current ADHD diagnosis, 14.5% in 2024. (HRSA, Jul 2026)
  • US girls aged 3–17: parent-reported current ADHD diagnosis, 8.8% in 2024. (HRSA, Jul 2026)
  • US all children aged 3–5: parent-reported current ADHD diagnosis, 2.7% in 2024. (HRSA, Jul 2026)
  • US boys aged 3–5: parent-reported current ADHD diagnosis, 3.7% in 2024. (HRSA, Jul 2026)
  • US girls aged 3–5: parent-reported current ADHD diagnosis, 1.6% in 2024. (HRSA, Jul 2026)

The NSCH reports different diagnosis percentages by age and sex. The following estimates use the same current-condition definition and household-survey year, making their denominators explicit. Lower recognition in preschool children should not be read as a screening result or as proof that symptoms first appear at school age.

What do the school-age and adolescent estimates show?

  • US all children aged 6–11: parent-reported current ADHD diagnosis, 12.5% in 2024. (HRSA, Jul 2026)
  • US boys aged 6–11: parent-reported current ADHD diagnosis, 16.2% in 2024. (HRSA, Jul 2026)
  • US girls aged 6–11: parent-reported current ADHD diagnosis, 8.7% in 2024. (HRSA, Jul 2026)
  • US all children aged 12–17: parent-reported current ADHD diagnosis, 14.8% in 2024. (HRSA, Jul 2026)
  • US girls aged 12–17: parent-reported current ADHD diagnosis, 12% in 2024. (HRSA, Jul 2026)

Current diagnoses remain common in the school-age and adolescent groups. These are population percentages within each listed group, not the composition of the ADHD population. Parent reports concern a professional diagnosis, but the survey did not independently reassess every child using a standardized diagnostic interview.

What care do children with ADHD use and struggle to obtain?

Service use and access problems can coexist. The US survey comparisons describe health care generally, so an emergency visit or hospital stay cannot automatically be attributed to ADHD.

How often do families report preventive and specialist care?

  • US children with current ADHD: two or more preventive visits in the previous year, 33.7% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: two or more preventive visits in the previous year, 22.7% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: one preventive visit in the previous year, 52.4% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: one preventive visit in the previous year, 55.1% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: no preventive visits in the previous year, 13.9% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: no preventive visits in the previous year, 22.1% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: a specialist visit in the previous year, 28.3% in 2024. (HRSA, Jul 2026)

Children with and without ADHD have different reported patterns of service use. Preventive visits refer to visits when the child was not sick or injured. Specialist visits exclude mental-health professionals. These comparisons do not isolate the effects of ADHD from co-occurring conditions or other family circumstances.

Which contacts and financial barriers appear in the survey?

  • US children without ADHD: a telehealth visit in the previous year, 11.6% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: a specialist visit in the previous year, 12.6% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: an emergency-room visit in the previous year, 22.7% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: an emergency-room visit in the previous year, 16.8% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: a hospital admission in the previous year, 2.9% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: unreasonable health-care costs in the previous year, 31.7% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: unreasonable health-care costs in the previous year, 26.9% in 2024. (HRSA, Jul 2026)

Families report both contacts with health services and difficulty meeting care needs. Telehealth includes video or telephone visits. Unreasonable costs mean costs were sometimes or never reasonable, according to the respondent; the measure is not an audited dollar amount or a direct estimate of treatment prices.

How should access barriers and severity be interpreted?

  • US children without ADHD: unmet health-care need in the previous year, 3.2% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: unmet specialist-care need among those needing specialist care in the previous year, 15.5% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: unmet specialist-care need among those needing specialist care in the previous year, 11.7% in 2024. (HRSA, Jul 2026)
  • US children without ADHD: less-than-very-satisfied parental care-coordination ratings in the previous year, 31.1% in 2024. (HRSA, Jul 2026)
  • US children with current ADHD: parent-rated mild ADHD, 41.9% in 2022. (Danielson et al. / CDC and HRSA, May 2024)
  • US children with current ADHD: parent-rated moderate ADHD, 45.3% in 2022. (Danielson et al. / CDC and HRSA, May 2024)
  • US children with current ADHD: parent-rated severe ADHD, 12.8% in 2022. (Danielson et al. / CDC and HRSA, May 2024)

Unmet needs and parent-rated severity describe different aspects of care. Specialist-care percentages apply to children needing that care; their ADHD-status difference was not statistically significant. Severity estimates concern an earlier survey year.

How does diagnosed ADHD vary among Canadian children?

Canadian estimates deserve their own frame. The table covers provincial household children and includes ADD in its diagnosis question, so direct numerical rankings against the US current-condition measure would overstate comparability.

What is the earlier Canadian school-age benchmark?

  • Canada, 2019: parent-reported diagnosed ADD/ADHD among all children aged 5 to 11, 7.5%. (Statistics Canada, Nov 2025)
  • Canada, 2019: parent-reported diagnosed ADD/ADHD among males aged 5 to 11, 10.6%. (Statistics Canada, Nov 2025)
  • Canada, 2019: parent-reported diagnosed ADD/ADHD among females aged 5 to 11, 4.2%. (Statistics Canada, Nov 2025)
  • Canada, 2019: parent-reported diagnosed ADD/ADHD among all children aged 12 to 17, 10%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among all children aged 1 to 17, 8.4%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among males aged 1 to 17, 10.8%. (Statistics Canada, Nov 2025)

The earlier cross-sectional survey provides a baseline for diagnosis recognition. These figures concern a health-professional diagnosis reported by the household respondent most knowledgeable about the child. They are not direct symptom measurements. The table excludes territories, institutional residents and other specified populations, including children living on First Nation reserves.

What does the later survey show across age and sex?

  • Canada, 2023: parent-reported diagnosed ADD/ADHD among females aged 1 to 17, 5.9%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among all children aged 5 to 11, 8.7%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among males aged 5 to 11, 11.8%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among females aged 5 to 11, 5.5%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among all children aged 12 to 17, 12.8%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among males aged 12 to 17, 15.8%. (Statistics Canada, Nov 2025)
  • Canada, 2023: parent-reported diagnosed ADD/ADHD among females aged 12 to 17, 9.8%. (Statistics Canada, Nov 2025)

The later Canadian cross-section also separates school-age children and adolescents. A higher reported percentage does not reveal how much reflects detection, access to assessment or changes in underlying need. Estimates describe the listed groups, and differences between point estimates require the survey's uncertainty information before being called statistically significant.

Which Canadian estimates describe the newest reference year?

  • Canada, 2024: parent-reported diagnosed ADD/ADHD among males aged 1 to 17, 12.2%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among females aged 1 to 17, 6.8%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among all children aged 5 to 11, 9.8%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among males aged 5 to 11, 13.3%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among females aged 5 to 11, 6.2%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among all children aged 12 to 17, 14.4%. (Statistics Canada, Nov 2025)
  • Canada, 2024: parent-reported diagnosed ADD/ADHD among males aged 12 to 17, 17.5%. (Statistics Canada, Nov 2025)

The newest reference year retains clear age and sex differences in reported diagnoses. These are provincial estimates instead of complete coverage of every Canadian child. The age reference date changed between survey cycles, and excluded nonresponses are removed from denominators. Those details matter when comparing adjacent years or planning services for a particular age group.

How has adolescent ADHD medication dispensing changed in Australia?

Dispensing identifies contact with treatment, not everyone with ADHD. The adolescent series is useful precisely because it keeps the population age range and administrative measure consistent across the displayed years.

What were adolescent patient rates before the recent rise?

The earlier annual observations establish the trajectory before the most recent increases. A patient rate counts adolescents receiving medication during the financial year relative to the resident adolescent population. It does not count tablets, prescriptions or days of treatment, and it does not imply that every diagnosed adolescent received medication.

How did the patient series develop in later years?

The later observations continue the upward pattern in recorded treatment contact. Financial years must remain attached to the values when they are quoted. Changes in diagnosis recognition, prescribing practice and eligibility can contribute to dispensing trends; these data alone do not determine the size of each contribution.

How do Australian adolescent dispensing rates differ by sex?

Separate male and female series reveal patterns hidden by the total. These categories come from administrative records, and the rate denominator is the corresponding resident population instead of all medication recipients.

What did the early male and female series look like?

Male patient rates were above female rates in the early years shown. Comparing the two within each financial year preserves the common age range. This difference concerns medication receipt recorded in the benefits system; it does not establish a biological prevalence ratio or measure the number of undiagnosed adolescents.

What changed in the middle of the series?

Both administrative series increased during these middle years. Each value is a population rate, so it should not be described as a percentage of diagnosed patients receiving appropriate treatment. The data also cannot distinguish adolescents using medication alone from those receiving behavioral, educational or other support alongside it.

What do the most recent sex-specific observations show?

Recent observations show more recorded medication patients among males. The female endpoint appears in the takeaways. Neither series measures adherence, clinical benefit or prescription suitability; records indicate supply through the covered system.

How many ADHD prescriptions are dispensed for adolescents?

Prescriptions and patients must never share a label. Repeat dispensing means a prescription rate can be much larger than a patient rate without implying that more individual adolescents are treated.

What do the earlier recent dispensing totals measure?

These annual dispensing rates count prescription events relative to the adolescent population. They are not average prescriptions per treated adolescent. A single patient can contribute multiple dispensings, while adolescents outside treatment remain in the population denominator. This distinction is essential when interpreting medicine supply alongside the patient series.

How should the latest sex-specific prescription rates be used?

The latest dispensing observations describe supply activity in the same adolescent age range. They do not measure dose, treatment duration, medication effectiveness or continuity of care. Differences between sexes combine the number of patients receiving medicines with dispensing patterns among those patients, so interpreting them requires both administrative measures.

Glossary

Methodology and sources

Every figure on this page comes from the organisation that produced it: regulators, statistics offices, public bodies, research institutes, and companies reporting their own data or surveys. Each one links to the original report or dataset and carries its release date. Survey results keep their population and fieldwork period, and financial figures keep the measure the producer used. Figures from different producers are not added together or ranked against each other. The page is reviewed monthly and updated when a producer releases newer data.